A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Randomised, double-blind, parallel group study to compare PK and PD profiles between HLX01
and rituximab (MabThera®) in patients with CD20+ B-cell Lymphoma.